(aryloxy)alkyl alicyclic amines as 5-HT7 receptor inverse agonists and the use thereof
Novel (aryloxy)alkyl alicyclic amine derivatives address the limitations of existing 5-HT7 receptor antagonists by providing enhanced selectivity and metabolic stability, effectively treating psychiatric and neurological disorders through potent inverse agonism.
Patent Information
- Application Number
- PCT/PL2026/050049
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-15
- Filing Date
- 2026-05-15
- Publication Date
- 2026-11-19
AI Technical Summary
Existing serotonin 5-HT7 receptor antagonists exhibit unfavorable pharmacokinetics and low metabolic stability, limiting their clinical development for treating psychiatric and neurological disorders.
Development of novel (aryloxy)alkyl alicyclic amine derivatives that act as potent inverse agonists with enhanced selectivity for the 5-HT7 receptor and improved metabolic stability, characterized by specific structural modifications such as aryl or heteroaryl substitutions and alicyclic diamines.
The compounds demonstrate high affinity for the 5-HT7 receptor with moderate to high selectivity towards related serotonin and dopaminergic receptors, offering therapeutic potential for disorders related to impaired 5-HT7 receptor-dependent signaling, including depression, anxiety, and neurodegenerative diseases.
Smart Images

Figure IMGF000002_0001 
Figure IMGF000002_0002 
Figure IMGF000003_0001
Abstract
Description
[0001] PK / 11501 / KZ
[0002] (Aryloxy)a I kyl alicyclic amines as 5-HT? receptor inverse agonists and the use thereof
[0003] The present invention relates to novel (aryloxy)alkyl alicyclic amine derivatives exhibiting the properties of inverse agonists of serotonin type 7 receptor as well as to pharmaceutical compositions comprising these compounds and their use as therapeutic agents. The compounds of the present invention can be used for the treatment of psychiatric and neurological disorders.
[0004] The serotonin type 7 (5-HT?) receptor is the latest representative of G protein-coupled serotonin receptors, which is coupled to adenylate cyclase through activation of Gs (Lovenberg et al., 1993). In addition, the 5-HT? receptor exhibits a high level of constitutive activity in the Gs-adenylate cyclase pathway (Andressen, et al., 2006, De Deurwaerdere et al., 2020). The highest concentration of 5-HT? receptors in the central nervous system is observed in regions involved in the control of multiple physiological functions, such as sleep, learning, and memory (i.e., suprachiasmatic nucleus, hippocampus, and prefrontal cortex).
[0005] The 5-HT7 receptor has become a clinically relevant target after its blockade was shown to exert antidepressant-like effect in animal models of depression and reversed cognitive decline related to neurodegenerative and neurological diseases. The initial search for the antagonists of the 5-HT7 receptor led to the identification of compound SB-269970 (Hagan et al., 2000).
[0006] While preclinical studies confirmed that SB-269970 exhibited an antidepressant effect when administered alone or in combination with low doses of antidepressants, its unfavorable pharmacokinetics and low metabolic stability prevented its further clinical development.
[0007] In addition to the potential efficacy in the treatment of behavioral disorders, including anxiety, depression, manic depression, mood disorders, affective disorders, the blocking of the 5-HT7 receptor may be potentially useful in the treatment of attention deficit hyperactivity disorder (ADHD), autism spectrum disorders, schizophrenia, panic attacks, as well as in the treatment of diseases related to neurodegeneration, pain or irritable bowel syndrome.
[0008] Structurally similar derivatives of the compounds of the present invention have been described previously (1). Application US20140135310 (Kotaczkowski et al., 2014) disclosed a series ofPK / 11501 / KZ
[0009] arylsulfonamide derivatives of alicyclic amines modified with various bicyclic systems (e.g. indole, benzoxazole, benzofuran) forming the terminal aryloxyl moiety (A), wherein said derivatives exhibited multi-receptor activity and features of potent non-selective serotonin 5-HT2A, 5-HTe, 5-HT?, and dopamine D2 and D3 receptor antagonists.
[0010]
[0011] 1
[0012] A = naphthyl or a 9- or 10-membered bicyclic heteroaryl; B = phenyl, naphthyl, cyclic or bicyclic heteroaryl; n = 2 or 3; I, m = 1 or 2; p = 0 or 1.
[0013] Zajdel et al. (Zajdel et al., 2012 and 2015, Canale et al., 2016 and 2017) disclosed a series of arylsulfonamide derivatives of (aryloxy)alkyl alicyclic amines of Formula (2), which exhibited features of 5-HT7 receptor antagonists and presented with low to moderate selectivity for serotonin 5-HTIA and dopamine D2 receptors.
[0014]
[0015] Z = isopropyl, tert-butyl, cyclopentyl, unsubstituted phenyl; n = 2 or 3; I, m = 1 or 2; p = 0 or 1;
[0016] R = H, F, Cl, methyl, methoxyl.
[0017] Although the antidepressant or anxiolytic effects exhibited by the selected compounds in rodent in vivo models were similar to those of SB-269970, the disclosed compounds were characterized by susceptibility to metabolic processes in in vitro assays. The compounds disclosed in those studies comprised an unsubstituted phenyl or a branched alkyl substituent within the aryloxy fragment, and an ethylene or propylene spacer between the aryloxyl and the diamine (i.e., 3-aminopyrrolidine, 4-aminopiperidine, 4-aminomethylpiperidine).
[0018] PK / 11501 / KZ
[0019] Thus, there is a need for compounds that strongly and selectively block the 5-HT? receptor while at the same time showing satisfactory metabolic stability (Gottlieb et al., 2023).
[0020] None of the above documents disclosed the compounds that are the subject of the present disclosure.
[0021] The present invention aims at providing novel potent inverse agonists at 5-HT? receptor characterized by enhanced selectivity over structurally related serotonin and dopaminergic receptors (i.e., 5-HTIA and D2) as well as favorable metabolic stability.
[0022] The present invention relates to compounds of general Formula I:
[0023]
[0024] wherein:
[0025] - Z is an aryl or heteroaryl substituted with group(s) selected from methoxyl, hydroxyl, and / or halogen, wherein heteroaryl is selected from 5- or 6-membered heteroaryl rings comprising a heteroatom selected from N or O;
[0026] - Ri is hydrogen or fluorine;
[0027] - n is 2 or 3,
[0028] - R2 is hydrogen, halogen, or methyl;
[0029] A is an alicyclic diamine of general Formula Gl, G2, G3, or G4:
[0030]
[0031] wherein k = 0 or 1; I = 0, 1, or 2; and m = 1 or 2;
[0032] PK / 11501 / KZ
[0033] or pharmaceutically acceptable salts thereof.
[0034] Preferably, A corresponds to substructure Gl,
[0035]
[0036] wherein k = 1, 1 = 0, m = 1, or wherein k = 0, 1 =0, m = 2, or wherein k = 0, 1 = 1, m = 1, or wherein k = 1, 1 = 2, m = 1, the most preferably wherein k = 0, 1 = 1, m = 1.
[0037] Preferably, A corresponds to substructure G2,
[0038]
[0039] G2
[0040] wherein I = 1 and m = 2, or wherein I = 2 and m = 2, the most preferably wherein I = 2 and m = 2.
[0041] Preferably, A corresponds to substructure G3,
[0042]
[0043] G3
[0044] wherein I = 1 and m = 1, or wherein I = 1 and m = 2, or wherein I = 2 and m = 2, the most preferably wherein I = 2 and m = 2.
[0045] Preferably, A corresponds to substructure G4,
[0046]
[0047] PK / 11501 / KZ
[0048] wherein I = 1 and m = 1, or wherein I = 1 and m = 2, preferably wherein I = 1 and m = 2.
[0049] The compounds of the invention have high affinity for 5-HT? receptor and moderate to high selectivity towards serotonin 5-HTIA, 5-HT2A, 5-HTe, and dopaminergic D2 receptors. Accordingly, the invention provides:
[0050] - a compound of general Formula (I) for use as a medicament.
[0051] - a pharmaceutical composition comprising a compound of Formula (I) as defined above or a pharmaceutically acceptable acid addition salt thereof in a therapeutically effective amount and in combination with one or more pharmaceutically acceptable carriers or diluents.
[0052] The present invention provides the use of a compound of Formula (I) as defined above, or an acid addition salt thereof, for the manufacture of a pharmaceutical formulation for the treatment of disorders as listed below.
[0053] The invention provides a compound of general Formula (I) or a pharmaceutically acceptable acid addition salt thereof for administration in a therapeutically effective amount for the treatment of disorders or conditions resulting from impaired 5-HT? receptor-dependent signaling transmission such as depression, anxiety disorder, panic disorder, obsessive-compulsive disorder, attention deficit hyperactivity disorder, autism spectrum disorder, schizophrenia, as well as for the treatment of diseases related to neurodegeneration, pain or irritable bowel syndrome.
[0054] The use of a compound of general Formula (I) or a pharmaceutically acceptable acid addition salt thereof for the preparation of medicament for use in the treatment of affective, neurodegenerative, or neurological diseases and conditions caused by abnormalities within the serotonin system in humans. In addition, the compound of general formula (I) or a pharmaceutically acceptable acid addition salt thereof can be used for the preparation of a medicament to be used in the treatment of disorders or conditions resulting from impaired5-HT7 receptor-dependent signaling transmission such as depression, anxiety disorder, panic disorder, obsessive-compulsive disorder, attention deficit hyperactivity disorder, autism spectrum disorder, schizophrenia, as well as in the treatment of diseases related to neurodegeneration, pain or irritable bowel syndrome
[0055] PK / 11501 / KZ
[0056]
[0057] The first variant of the compounds of Formula (I) consists of compounds such as the one presented above, wherein A corresponds to substructure G1 and n = 3.
[0058]
[0059] The first subgroup within said first variant is represented by compounds where k = 1, 1 = 1, and m = 0. In this case, substructure G1 is 3-aminomethylpyrrolidine.
[0060] The second subgroup within said first variant is represented by compounds where k = 0, 1 = 2, and m = 0. In this case, substructure G1 is 3-aminopiperidine.
[0061] The third subgroup within said first variant is represented by compounds where k = 0, 1 = 1, and m = 1. In this case, substructure G1 is 4-aminopiperidine.
[0062] The fourth subgroup within said first variant is represented by compounds where k = 0, I = 2, and m = 1. In this case, substructure G1 is 3-aminoazepine.
[0063] The preferred embodiment of the invention within this subgroup consists of compounds where k = 0, 1 = 1, and m = 1.
[0064] The second variant of the compounds of Formula (I) consists of compounds as presented above, wherein A corresponds to substructure G2 and n = 2.
[0065]
[0066] G2
[0067] The first subgroup within said second variant is represented by compounds where I = 1, and m = 2. In this case, substructure G2 is 2,6-diazaspiro[3.4]octane.
[0068] PK / 11501 / KZ
[0069] The second subgroup within said second variant is represented by compounds where I = 2, and m = 2. In this case, substructure G2 is 2,7-diazaspiro[3.5]nonane.
[0070] The third variant of the compounds of Formula (I) consists of compounds as presented above, wherein A corresponds to substructure G3 and n = 2.
[0071]
[0072] The first subgroup within said third variant is represented by compounds where I = 1, and m = 1. In this case, substructure G3 is 2,6-diazaspiro[3.4]octane.
[0073] The second subgroup within said third variant is represented by compounds where I = 1, and m = 2. In this case, substructure G3 is 2,7-diazaspiro[4.4]nonane.
[0074] The third subgroup within said third variant is represented by compounds where I = 2, and m = 2. In this case, substructure G3 is 2,8-diazaspiro[4.5]decane.
[0075] The preferred embodiment of the invention within this subgroup consists of compounds where I = 2, and m = 2.
[0076] The fourth variant of the compounds of Formula (I) consists of compounds such as the one presented above, wherein A corresponds to substructure G4 and n = 2.
[0077]
[0078] The first subgroup within said fourth variant is represented by compounds where I = 1, and m = 1. In this case, substructure G4 is 2,7-diazaspiro[3.5]nonane.
[0079] The second subgroup within said fourth variant is represented by compounds where I = 1, and m = 2. In this case, substructure G4 is 2,8-diazaspiro[4.5]decane.
[0080] PK / 11501 / KZ
[0081] A preferred embodiment of the invention is a compound of Formula (I) as above, wherein the compound is:
[0082] ( / ?)- / V-[(l-{3-[(3-Fluoro-4'-hydroxy-[l,l'-biphenyl]-2-yl)oxy]propyl}pyrrolidin-3-yl)methyl]benzenesulfonamide;
[0083] 3-Chloro- / V-(l-{3-[(4'-hydroxy-[l,l'-biphenyl]-2-yl)oxy]propyl)piperidin-4-yl}benzenesulfonamide;
[0084] 4-Fluoro- / V-(l-{3-[(4'-hydroxy-[l,l'-biphenyl]-2-yl)oxy]propyl}piperidin-4-yl)benzenesulfonamide;
[0085] / V-(l-{3-[(4'-Hydroxy-[l,l'-biphenyl]-2-yl)oxy]propyl}piperidin-4-yl)-4-methylbenzenesulfonamide;
[0086] / V-(l-{3-[(3-Fluoro-4'-hydroxy-[l,l'-biphenyl]-2-yl)oxy]propyl}piperidin-4-yl)benzenesulfonamide;
[0087] ( / ?)- / V-(l-{3-[(3-Fluoro-4'-hydroxy-[l,l'-biphenyl]-2-yl)oxy]propyl}azepan-4-yl)benzenesulfonamide;
[0088] 6-[2-([l,l'-Biphenyl]-2-yloxy)ethyl]-2-[(4-fluorophenyl)sulfonyl]-2,6-diazaspiro[3.4]octane;
[0089] 3'-Fluoro-2'-{2-[2-(phenylsulfonyl)-2,7-diazaspiro[3.5]nonan-7-yl]ethoxy}-[l,l'-biphenyl]-4-ol;
[0090] 2-[2-([l,l'-Biphenyl]-2-yloxy)ethyl]-6-[(4-fluorophenyl)sulfonyl]-2,6-diazaspiro[3.4]octane;
[0091] 2-{2-[(3-Fluoro-[l,l'-biphenyl]-2-yl)oxy]ethyl}-7-(phenylsulfonyl)-2,7-diazaspiro[4.4]nonane;
[0092] 8-[2-([l,l'-Biphenyl]-2-yloxy)ethyl]-2-[(4-fluorophenyl)sulfonyl]-2,8-diazaspiro[4.5]decane;
[0093] 2'-(2-{7-[(4-Fluorophenyl)sulfonyl]-2,7-diazaspiro[3.5]nonan-2-yl}ethoxy)-[l,l'-biphenyl]-4-ol;
[0094] 7-[(4-Fluorophenyl)sulfonyl]-2-{2-[2-(furan-3-yl)phenoxy]ethyl}-2,7-diazaspiro[3.5]nonane;
[0095] 2-{2-[(3-Fluoro-[l,l'-biphenyl]-2-yl)oxy]ethyl}-7-(phenylsulfonyl)-2,7-diazaspiro[3.5]nonane;
[0096] 2-{2-[(3-Fluoro-4'-methoxy-[l,l'-biphenyl]-2-yl)oxy]ethyl}-7-(phenylsulfonyl)-2,7-diazaspiro[3.5]nonane;
[0097] PK / 11501 / KZ
[0098] 2-{2-[(3-Fluoro-4'-methoxy-[l,l'-biphenyl]-2-yl)oxy]ethyl}-7-[(4-fluorophenyl)sulfonyl]-2,7-diazaspiro[3.5]nonane;
[0099] 2-{2-[(3-Fluoro-[l,l'-biphenyl]-2-yl)oxy]ethyl}-8-(phenylsulfonyl)-2,8-diazaspiro[4.5]decane;
[0100] 3'-Fluoro-2'-{2-[8-(phenylsulfonyl)-2,8-diazaspiro[4.5]decan-2-yl]ethoxy}-[l,l'-biphenyl]-4-ol;
[0101] 2-{2-[2-Fluoro-6-(pyridin-3-yl)phenoxy]ethyl}-8-(phenylsulfonyl)-2,8-diazaspiro[4.5]decane.
[0102] The most preferred embodiment of the invention is a compound of Formula (I) as above, selected from the following:
[0103] 3-Chloro- / V-(l-{3-[(4'-hydroxy-[l,l'-biphenyl]-2-yl)oxy]propyl)piperidin-4-yl}benzenesulfonamide;
[0104] 4-Fluoro- / V-(l-{3-[(4'-hydroxy-[l,l'-biphenyl]-2-yl)oxy]propyl}piperidin-4-yl)benzene sulfonamide;
[0105] / V-(l-{3-[(3-Fluoro-4'-hydroxy-[l,l'-biphenyl]-2-yl)oxy]propyl}piperidin-4-yl)benzenesulfonamide;
[0106] 2-{2-[(3-Fluoro-[l,l'-biphenyl]-2-yl)oxy]ethyl}-7-(phenylsulfonyl)-2,7-diazaspiro[3.5]nonane;
[0107] 2-{2-[(3-Fluoro-4'-methoxy-[l,l'-biphenyl]-2-yl)oxy]ethyl}-7-(phenylsulfonyl)-2,7-diazaspiro[3.5]nonane;
[0108] 2-{2-[(3-Fluoro-4'-methoxy-[l,l'-biphenyl]-2-yl)oxy]ethyl}-7-[(4-fluorophenyl)sulfonyl]-2,7-diazaspiro[3.5]nonane;
[0109] 2-{2-[(3-Fluoro-[l,l'-biphenyl]-2-yl)oxy]ethyl}-8-(phenylsulfonyl)-2,8-diazaspiro[4.5]decane;
[0110] 3'-Fluoro-2'-{2-[8-(phenylsulfonyl)-2,8-diazaspiro[4.5]decan-2-yl]ethoxy}-[l,l'-biphenyl]-4-ol.
[0111] The term "5- or 6-membered ring" refers to an aryl or heteroaryl ring, such as phenyl, pyridyl, furanyl, thienyl, pyrazolyl.
[0112] The term "substituted" as used in the definition of a compound described in the invention means that a particular group or moiety comprises one or more substituents. In the case where any group may comprise a plurality of substituents and a variety of possible substituents is provided, the substituents are selected independently and need not be the same.
[0113] PK / 11501 / KZ
[0114] The term "unsubstituted" or no substitution being mentioned means that the specified group does not contain substituents other than hydrogen atoms.
[0115] The term "halogen" refers to fluorine, chlorine, bromine or iodine. Among the halogen atoms, fluorine and chlorine are preferred.
[0116] In the case where the compound of Formula (I) according to the invention comprises a chiral centre, it is to be intended that it may be provided in the form of optical isomers or mixtures thereof. Such optical isomersand mixtures containing these isomers in various ratios, including racemic mixtures, are within the scope of the invention. This is particularly true for compounds of Formula (I), where A corresponds to substructure Gl, n = 3, k = 1, 1 = 1, and m = 0, or where k = 0, 1 = 2, and m = 1.
[0117] The salts of the inventive compounds of Formula (I) include salts with pharmaceutically acceptable inorganic or organic acids. Inorganic and organic acids that can form pharmaceutically acceptable salts with compounds containing a basic nitrogen atom are well known in the art. In particular, salts with inorganic acids may include salts of hydrochloric, hydrobromic, sulfuric and phosphoric acids. In particular, salts with organic acids may include salts with methanesulfonic, toluenesulfonic, benzenesulfonic, naphthalene disulfonic, acetic, propionic, lactic, malic, citric, fumaric, oxalic and benzoic acids.
[0118] Pharmaceutically acceptable salts can be prepared in a simple manner by reaction of a compound of Formula (I) with a suitable inorganic or organic acid, optionally in suitable organic solvents, to form a salt that is usually isolated, for example, by crystallization and filtration.
[0119] While it is possible for the compounds of Formula (I) to be provided as raw chemical materials, it is preferred to prepare them as a "pharmaceutical composition". In a further aspect, the present invention provides a pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable carriers or diluents and optionally one or more other therapeutic ingredients. The carrier(s) must be "acceptable" in the sense that they are compatible with the other ingredients of the formulation and not harmful to the recipient.
[0120] The term "composition" as used herein includes a product comprising particular ingredients in particular quantities or proportions, as well as any product that results directly or indirectly from the combination of particular ingredients in particular quantities. As used herein, thePK / 11501 / KZ
[0121] term "pharmaceutical compositions" encompasses a product comprising one or more active ingredients and an optimal carrier comprising inactive ingredients, as well as any product that results directly or indirectly from the combination, complexation or aggregation of any two or more ingredients, or from the dissociation of one or more ingredients, or from other types of reaction or interaction of one or more ingredients.
[0122] In general, pharmaceutical compositions are prepared by uniformly and accurately combining the active ingredients with a liquid carrier or finely ground solid carrier or both, and then, if necessary, bringing the product to the desired form. The pharmaceutical composition comprises a sufficient amount of the active compound of the present invention and a pharmaceutically acceptable carrier.
[0123] A typical daily dose of active ingredients varies widely and depends on a variety of factors, such as the indication, route of administration, age, weight, and gender of the patient, and can be determined by the physician. In general, the total daily dose administered to the patient as a single or individual dose may be, for example, in the range of 0.001 to 10 mg / kg body weight per day, more typically in the range of 0.01 to 1000 mg of total active ingredients per day.
[0124] The compounds of the invention may be obtained by one of the following methods, including:
[0125] The inventive compounds of general Formula (I) -arylsulfonamide derivatives of (aryloxy)alkyl alicyclic amines - can be obtained from compounds of Formula (II) wherein A, Z, and Ri are groups as defined for the general structure (I), in reaction with commercially available arylsulfonyl chloride (Ar-SCh-CI) where R2 is a group as defined in general Formula (I). The reaction of the compound of Formula (II) with arylsulfonyl chloride selected from a group including but not limited to: 3-chlorobenzenesulfonyl chloride, 4-fluorobenzenesulfonyl chloride, or 4-toluenesulfonyl chloride, was carried out after prior removal of the Boc protecting group using a mixture of trifluoroacetic or hydrochloric acid and dichloromethane. The synthesis of arylsulfonamides may be carried out in an organic solvent, including but not limited to dichloromethane, in the presence of a tertiary proton-capturing amine including, but not limited to, triethylamine, at a temperature of about 0 °C.
[0126] PK / 11501 / KZ
[0127]
[0128] Compounds of Formula (II) are synthesized via Suzuki coupling reaction between halide derivatives of general Formula (III), wherein X is Cl or Br, and Ri is a group as defined in general Formula (I), and commercially available aryl / heteroaryl boronic acids (Ar-(BOH)2) selected from but not limited to: phenylboronic acid, 4-hydroxyboronic acid, 4-methoxyboronic acid, 3-pyridoboronic acid, and 3-furanoboronic acid, under microwave-assisted conditions using a palladium catalyst including, but not limited to, tetrakis(triphenylphosphine)palladium (0), in an alkaline medium including, but not limited to, a K2CO3 solution in a water / dioxane mixture (1 / 3; v / v).
[0129] Compounds of general Formula (III) were obtained by a two-step synthesis method involving alkylation of differently substituted phenols in the presence of a suitable dibromoalkane, followed by alkylation of a primary or secondary alicyclic diamine protected by the Boc protection group , selected from but not limited to: ( / ?)-3-aminomethylpyrrolidine, 4-aminopiperidine, ( / ?) -3-aminoazepine, 2,6-diazaspiro [3.4]octane, 2,7-diazaspiro [3.5]nonane, 2,7-diazaspiro [4.4]nonane, 2,8-diazaspiro [4.5]decane, in an alkaline environment, in accordance with the procedures described by Zajdel, P., et al. 2015.
[0130]
[0131] EXAMPLES
[0132] 1 Synthesis
[0133] The method of preparing the compounds of the invention is illustrated in the following Examples. The syntheses presented in the examples were not optimized in terms of yield, the quantities of reagents used, as well as the final form of the compounds obtained.
[0134] PK / 11501 / KZ
[0135] Analytical grade organic solvents as provided by Merck and Chempur were used without further purification. Commercially available reagents of the highest purity grade (>97%) were purchased from Fluorochem, Ambeed, and Spirochem. Column chromatography was performed on silica gel 60 (70-230 mesh) purchased from Merck.
[0136] List of abbreviations: CH3CN: acetonitrile; EtOAc: ethyl acetate; Hex: n-hexane; MeOH: methanol; K2CO3: potassium carbonate; KI: potassium iodide; NazSC : sodium sulfate; Pd(PPh3)4: tetrakis(triphenylphosphine)palladium(0); TEA: triethylamine; TFA: trifluoroacetic acid.
[0137] Microwave-assisted reactions were carried out in a Biotage® lnitiator+ microwave synthesizer. Mass spectra were recorded on a UPLC-MS / MS system consisting of the Waters Acquity l-Class Plus apparatus coupled with the Waters Synapt XS mass spectrometer (electrospray ionization [ESI] mode). Chromatographic separation was carried out using an Acquity UPLC BEH column and linear gradient of eluent A, 95 to 0% over 10 min, flow rate: 0.3 mL-min-1. The retention times, tR, are given in minutes. UPLC / MS purity of all final compounds and key intermediates has been confirmed to be 95% or higher. Proton and carbon (1H NMR and13C) NMR spectra were recorded on a JEOL JNMECZR 500 RSI (500 and 126 MHz) spectrometer and expressed in ppm with deuterated chloroform (CDCI3, CAS: 865-49-6) used for calibration. J values are given in hertz (Hz).
[0138] 1.1 Alkylation of 2-bromo-6-fluorophenol
[0139] A solution of 1,3-dibromopropane (11.3 mL, 0.12 mol, 4 eq., CAS: 109-64-8) in CH3CN (15 mL, CAS: 75-05-8) was added dropwise to a mixture of 2-bromo-6-fluorophenol (5.73 g, 0.03 mol, 1 eq., CAS: 2040-89-3) and K2CO3 (12.44 g, 0.09 mol, 3 eq., CAS: 584-08-7) in CH3CN (25 mL). The reaction was continued under reflux for 48 h. Inorganic residues were filtered out and the organic mixture was concentrated under reduced pressure. The resulting crude product 1 was purified on silica gel using a EtOAc / Hex (1 / 9, v / v) as eluting system.
[0140] Intermediate 1: l-Bromo-2-(3-bromopropoxy)-3-fluorobenzene
[0141]
[0142] PK / 11501 / KZ
[0143] Colorless oil, 7.21 g (isolated yield 77%); UPLC / MS purity = 98%, tR= 7.56 min; C9H9Br2FO, MW 311.98, monoisotopic mass 309.90.XH NMR (500 MHz, CDCI3) 6 ppm 4.22 (t, J = 5.9 Hz, 2H), 3.61 (t, J = 6.3 Hz, 2H), 2.35-2.39 (m, 2H), 6.92 (td, J = 8.3, 5.2 Hz, 1H), 7.06 (ddd, J = 10.6, 8.3, 1.5 Hz, 1H), 7.31 (dt, J = 8.1, 1.5 Hz, 1H).
[0144] 1.2 General procedure for the preparation of Intermediates 2-13
[0145] An example reaction was carried out as follows. Commercial tert-butyl ( / ?)-(pyrrolidin-3-ylmethyl)carbamate (1 g, 5.0 mmol, 1 eq., CAS: 173340-25-5) was dissolved in CH3CN (20 mL). K2CO3 (2.07 g, 15.0 mmol, 3 eq.) and a catalytic amount of KI (CAS: 7681-11-0) were then added followed by dropwise addition of l-bromo-2-(3-bromopropoxy)-3-fluorobenzene (1.87 g, 6.0 mmol, 1.2 eq.) as an alkylating agent. The reaction was continued under reflux for 24 h. Inorganic residues were filtered out and the organic mixture was concentrated under reduced pressure. The resulting crude product 2 was purified on silica gel using a EtOAc / Hex mixture (1 / 9, v / v) as eluting system. Further intermediates 3-13 were synthesized using suitable commercially available alicyclic diamines and selected alkylating reagents according to the procedure described above.
[0146] Intermediate 2: tert-Butyl ( / ?)-({l-[3-(2-bromo-6-fluorophenoxy)propyl]pyrrolidin-3-yl}methyl)carbamate
[0147]
[0148] White solid, 1.54 g (isolated yield 72%); UPLC / MS purity = 97%, tR= 5.91 min; CigH28BrFN2O3, MW 430.35, monoisotopic mass 430.13, [M+H]+431.1.TH NMR (500 MHz, CDCI3) 6 ppm 1.44 (s, 9H), 1.48-1.64 (m, 2H), 1.95-2.09 (m, 2H), 2.10-2.22 (m, 2H), 2.38-2.49 (m, 2H), 2.76-2.98 (m, 3H), 3.02 (t, J = 5.3 Hz, 2H) 3.11-3.20 (m, 2H), 4.19 (t, J = 5.3 Hz, 2H), 4.87 (br. s., 1H), 6.92 (td, J = 8.3, 5.2 Hz, 1H), 7.06 (ddd, J = 10.6, 8.3, 1.5 Hz, 1H), 7.31 (dt, J = 8.1, 1.5 Hz, 1H).
[0149] Intermediate 3: tert-Butyl {l-[3-(2-iodophenoxy)propyl]piperidin-4-yl}carbamate
[0150] PK / 11501 / KZ
[0151]
[0152] White solid, 4.60 g (80% isolated yield); UPLC / MS purity = 100%, tR = 4.78 min; C19H29IN2O3, MW 460.35, monoisotopic mass 460.12, [M+H]+461.2.XH NMR (500 MHz, CDCI3) 6 ppm 1.44 (s, 9H), 1.61-1.74 (m, 2H), 1.97-2.07 (m, 2H), 2.10-2.22 (m, 2H), 2.26-2.40 (m, 2H), 2.73-2.85 (m, 2H), 2.99-3.18 (m, 2H), 3.47-3.63 (m, 1H), 4.08 (t, J = 5.9 Hz, 2H), 4.44-4.57 (m, 1H), 6.71 (td, J = 7.6, 1.3 Hz, 1H), 6.80 (dd, J = 8.3, 1.4 Hz, 1H), 7.28 (ddd, J = 8.2, 7.4, 1.6 Hz, 1H), 7.75 (dd, J = 7.8, 1.6 Hz, 1H).13C NMR (126 MHz, CDCI3) 6 ppm 28.5, 55.3, 67.1, 86.8, 112.3, 122.8, 129.6, 129.7, 139.5, 139.6, 155.3, 157.3.
[0153] Intermediate 4: tert-Butyl {l-[3-(2-bromo-6-fluorophenoxy)propyl]piperidin-4-yl}carbamate
[0154]
[0155] Light yellow oil, 3.67 g (70% isolated yield); UPLC / MS purity = 98%, LR = 5.75 min; Ci9H28BrFN2O3, MW 431.34, monoisotopic mass 430.13, [M+H]+431.0 / 433.0.TH NMR (500 MHz, CDCI3) 6 ppm 1.43 (s, 9H), 1.64-1.76 (m, 2H), 2.02 (dd, J = 12.7, 3.9 Hz, 2H), 2.13 (t, J = 7.5 Hz, 2H), 2.36 (br. s., 2H), 2.82 (t, J = 7.7 Hz, 2H), 3.09 (br. s., 2H), 3.57 (br. s., 1H), 4.14 (t, J = 6.0 Hz, 2H), 4.53 (br. s., J = 8.0 Hz, 1H), 6.91 (td, J = 8.2, 5.3 Hz, 1H), 7.04 (ddd, J = 10.6, 8.3, 1.5 Hz, 1H), 7.30 (dt, J = 8.1, 1.5 Hz, 1H).
[0156] Intermediate 5: ( / ?)-tert-Butyl {l-[3-(2-bromo-6-fluorophenoxy)propyl]azepan-3-yl}carbamate
[0157]
[0158] Colorless oil, 1.40 g (67% isolated yield); UPLC / MS purity = 96%, tR = 5.95 min; C2oH3oBrFN203, MW 445.37, monoisotopic mass 444.14, [M+H]+445.1.TH NMR (500 MHz, CDCI3) 6 ppm 1.44 (s, 9H), 1.37-1.51 (m, 2H), 1.52-1.79 (m, 4H), 1.82-1.95 (m, 3H), 2.53-2.62 (m, 1H), 2.62-2.73PK / 11501 / KZ
[0159] (m, 1H), 2.77-2.94 (m, 2H), 3.00 (t, J = 5.3 Hz, 2H), 3.72-3.86 (m, 1H), 4.00-4.14 (m, 2H), 6.93 (td, J = 8.3, 5.2 Hz, 1H), 7.04 (ddd, J = 10.6, 8.3, 1.5 Hz, 1H), 7.31 (dt, J = 8.3, 1.5 Hz, 1H).
[0160] Intermediate 6: tert-Butyl 6-[2-(2-iodophenoxy)ethyl]-2,6-diazaspiro[3.4]octane-2-carboxylate
[0161]
[0162] Colorless oil, 1.35 g (70% isolated yield); UPLC / MS purity = 100%, tR = 5.03 min; C19H27IN2O3, MW 458.34, monoisotopic mass 458.11, [M+H]+459.3.XH NMR (500 MHz, CDCI3) 6 ppm 1.43 (s, 9H), 2.13 (t, J = 7.1 Hz, 2H), 2.92 (s, 2H), 3.07 (s, 4H), 3.86 (d, J = 8.6 Hz, 2H), 3.93 (d, J = 8.6 Hz, 2H), 4.21 (t, J = 5.1 Hz, 2H), 6.73 (td, J = 7.6, 1.3 Hz, 1H), 6.81 (dd, J = 8.3, 1.4 Hz, 1H), 7.29 (ddd, J = 8.2, 7.4, 1.7 Hz, 1H), 7.77 (dd, J = 7.8, 1.6 Hz, 1H).
[0163] Intermediate 7: tert-Butyl 7-[2-(2-bromo-6-fluorophenoxy)ethyl]-2,7-diazaspiro[3.5]nonane-2-carboxylate
[0164]
[0165] Colorless oil, 1.39 g (71% isolated yield); UPLC / MS purity = 98%, tR = 8.84 min; C2oH2sBrFN203, MW 443.35, monoisotopic mass 442.13, [M+H]+443.0.TH NMR (500 MHz, CDCI3) 6 ppm 1.43 (s, 9H), 1.46-1.65 (m, 4H), 2.13-2.49 (m, 4H), 2.62-2.81 (m, 2H), 3.43 (s, 4H), 4.08 (br. s., 2H), 6.91 (td, J = 8.2, 5.3 Hz, 1H), 7.04 (ddd, J = 10.6, 8.3, 1.5 Hz, 1H), 7.30 (dt, J = 8.1, 1.5 Hz, 1H).
[0166] Intermediate 8: tert-Butyl 2-[2-(2-iodophenoxy)ethyl]-2,6-diazaspiro[3.4]octane-6-carboxylate
[0167]
[0168] PK / 11501 / KZ
[0169] Colorless oil, 1.27 g (75% isolated yield); UPLC / MS purity = 99%, tR = 8.10 min; C19H27IN2O3, MW 458.34, monoisotopic mass 458.11, [M+H]+459.2.TH NMR (500 MHz, CDCI3) 6 ppm 1.45 (s, 9H), 1.85 (td, J = 7.0, 2.1 Hz, 2H), 2.67-2.73 (m, 2H), 2.81 (br. s., 2H), 3.18 (td, J = 7.0, 2.2 Hz, 2H), 3.23 (d, J = 2.2 Hz, 2H), 3.93 (td, J = 5.5, 2.2 Hz, 2H), 4.08 (m, 2H), 6.73 (td, J = 7 A, 1.4 Hz, 1H), 6.81 (dd, J = 8.2, 1.4 Hz, 1H), 7.29 (ddd, J = 8.2, 7.4, 1.4 Hz, 1H), 7.77 (dd, J = 7 A, 1.4 Hz, 1H).
[0170] Intermediate 9: tert-Butyl 7-[2-(2-bromo-6-fluorophenoxy)ethyl]-2,7-diazaspiro[4.4]nonane-2-carboxylate
[0171]
[0172] Colorless oil, 1.38 g (70% isolated yield); UPLC / MS purity = 99%, tR = 5.68 min; C2oH2sBrFN203, MW 443.36, monoisotopic mass 442.13, [M+H]+443.2.TH NMR (500 MHz, CDCI3) 6 ppm 1.44 (s, 9H) 1.74-1.94 (m, 4H) 2.49-3.05 (m, 6H), 3.16-3.28 (m, 1H) 3.29-3.43 (m, 3H), 4.12-4.28 (m, 2H), 6.90 (d, J = 5.3 Hz, 1H), 7.03 (s, 1H) 7.29 (d, J = 8.1 Hz, 1H).
[0173] Intermediate 10: tert-Butyl 8-[2-(2-iodophenoxy)ethyl]-2,8-diazaspiro[4.5]decane-2-carboxylate
[0174]
[0175] Colorless oil, 1.54 g (76% isolated yield); UPLC / MS purity= 97%, tR = 8.35 min; C21H31IN2O3, MW 486.39, monoisotopic mass 486.14, [M+H]+487.3.XH NMR (500 MHz, CDCI3) 6 ppm 1.46 (s, 9H), 1.53-1.71 (m, 6H), 2.27-2.70 (m, 4H), 2.84 (s, 2H), 3.10 (d, J = 38.8 Hz, 2H), 3.35 (dt, J = 24.9, 7.1 Hz, 2H), 4.17 (s, 2H), 6.73 (td, J = 7 A, 1.4 Hz, 1H), 6.81 (dd, J = 8.2, 1.4 Hz, 1H), 7.29 (ddd, J = 8.2, 7.4, 1.4 Hz, 1H), 7.77 (dd, J = 7 A, 1.4 Hz, 1H).
[0176] Intermediate 11: tert-Butyl 2-[2-(2-iodophenoxy)ethyl]-2,7-diazaspiro[3.5]nonane-7-carboxylate
[0177] PK / 11501 / KZ
[0178]
[0179] White solid, 1.67 g (80% isolated yield); purity UPLC / MS = 100%, tR = 8.54 min, C20H29IN2O3, MW 472.36, monoisotopic mass 472.12, [M+H]+473.2.XH NMR (500 MHz, CDCI3) 6 ppm 1.44 (s, 9H), 1.75 (t, J = 5.7 Hz, 4H), 3.07 (t, J = 5.4 Hz, 2H), 3.34 (t, J = 5.7 Hz, 4H), 3.40 (s, 4H), 4.12 (t, J = 5.3 Hz, 2H), 6.71 (t, J = 7.6 Hz, 1H), 6.79 (d, J = 8.2 Hz, 1H), 7.26-7.31 (m, 1H), 7.76 (dd,
[0180] J = 7.8, 1.5 Hz, 1H).13C NMR (126 MHz, CDCI3) 6 ppm 28.6, 35.2, 35.8, 57.5, 65.5, 68.1, 79.7, 86.3, 112.2, 123.0, 129.7, 139.7, 155.0, 157.4.
[0181] Intermediate 12: tert-Butyl 2-[2-(2-bromo-6-fluorophenoxy)ethyl]-2,7-diazaspiro[3.5]nonane-7-carboxylate
[0182]
[0183] Colorless oil, 1.51 g (77% isolated yield); UPLC / MS purity = 98%, tR = 8.88 min; C2oH2sBrFN203, MW 443.35, monoisotopic mass 442.13, [M+H]+443.0.TH NMR (500 MHz, CDCI3) 6 ppm 1.44 (s, 9H), 1.71-1.79 (m, 4H), 3.03 (t, J = 5.5 Hz, 2H), 3.30-3.40 (m, 8H), 4.15 (t, J = 5.5 Hz, 2H), 6.92 (td, J = 8.2, 5.3 Hz, 1H), 7.04 (ddd, J = 10.4, 8.3, 1.5 Hz, 1H), 7.30 (dt, J = 8.1, 1.5 Hz, 1H).
[0184] 13C NMR (126 MHz, CDCI3) 6 ppm 28.6, 28.7, 35.0, 35.8, 58.4, 64.7, 72.0, 72.1, 79.6, 116.2,
[0185] 116.4, 117.9, 118.0, 124.9, 128.5, 144.5, 155.0, 156.2, 157.2.
[0186] Intermediate 13: tert-Butyl 2-[2-(2-bromo-6-fluorophenoxy)ethyl]-2,8-diazaspiro[4.5]decane- 8-carboxylate
[0187]
[0188] PK / 11501 / KZ
[0189] Colorless oil, 1.31 g (69% isolated yield); UPLC / MS purity = 97%, tR = 8.10 min; CziHsoBrFNzCh, MW 456.38, monoisotopic mass 456.14, [M+H]+457.2.XH NMR (500 MHz, CDCI3) 6 ppm 1.44 (s, 9H), 1.39-1.49 (m, 2H), 1.59 (dd, J = 13.4, 7.4 Hz, 4H), 2.25-2.35 (m, 2H), 2.58 (s, 2H), 2.79 (s, 2H), 2.83-2.91 (m, 2H), 2.98-3.05 (m, 2H), 4.02-4.12 (m, 2H), 6.92 (td, J = 8.2, 5.3 Hz, 1H), 7.04 (ddd, J = 10.4, 8.3, 1.5 Hz, 1H), 7.30 (dt, J = 8.1, 1.5 Hz, 1H).
[0190] 1.3 General procedure for the preparation of intermediates 14-27
[0191] An example reaction was carried out as follows. Intermediate 2 (0.5 g, 1.16 mmol, 1 eq.), (4-hydroxyphenyl)boronic acid (0.191 g, 1.39 mmol, 1.1 eq., CAS: 71597-85-8), K2CO3 (0.452 g, 3.27 mmol, 3 eq.) and Pd(PPh3)4(0.058 g, 0.109 mmol, 0.05 eq., CAS: 14221-01-3) were solubilized in a mixture of 1,4-dioxane / water (3 / 1, v / v) and heated at 140 °C for 2 h in a microwave reactor. The reaction mixture was diluted with EtOAc (CAS: 141-78-6), filtered through Celite (CAS: 68855-54-9), washed with water and brine, dried over NazSC (CAS: 7757-82-6) and concentrated under reduced pressure. The resulting crude product 14 was purified on silica gel using a CHzCb / MeOH mixture (9 / 0.5, v / v) as eluting system. Further intermediates 14-27 were synthesized using suitable aryl halides 3-13 and selected commercially available aryl / heteroaryl boronic acids according to the procedure described above.
[0192] Intermediate 14: tert-Butyl ( / ?)-[(l-{3-[(3-fluoro-4'-hydroxy-[l,l'-biphenyl]-2-yl)oxy]propyl}pyrrolidin-3-yl)methyl]carbamate
[0193]
[0194] Light yellow oil, 0.319 g (62% isolated yield); UPLC / MS purity = 96%, tR = 4.47 min; C25H33FN2O4, MW 444.55, monoisotopic mass 444.24, [M+H]+445.3.TH NMR (500 MHz, CDCI3) 6 ppm 1.44 (s, 9H), 1.48-1.64 (m, 2H), 1.95-2.09 (m, 2H), 2.10-2.22 (m, 2H), 2.38-2.49 (m, 2H), 2.76-2.98 (m, 3H), 3.02 (t, J = 5.6 Hz, 2H), 4.19 (t, J = 5.6 Hz, 2H), 4.87 (br. s., 1H), 6.90-6.95 (m, 2H), 6.98-7.12 (m, 3H), 7.40-7.50 (m, 2H).
[0195] PK / 11501 / KZ
[0196] Intermediate 15: tert-Butyl (l-{3-[(4'-hydroxy-[l,l'-biphenyl]-2-yl)oxy]propyl}piperidin-4-yl)carbamate
[0197]
[0198] Colorless oil, 0.284 g (61% isolated yield); UPLC / MS purity = 97%, tR = 4.34 min; C25H34N2O4, MW 426.56, monoisotopic mass 426.25, [M+H]+427.3.XH NMR (500 MHz, CDCI3) 6 ppm 1.44 (s, 9H), 1.61-1.74 (m, 2H), 1.97-2.07 (m, 2H), 2.10-2.22 (m, 2H), 2.26-2.40 (m, 2H), 2.73-2.85 (m, 2H), 2.99-3.18 (m, 2H), 3.47-3.63 (m, 1H), 4.08 (t, J = 5.9 Hz, 2H), 4.44-4.57 (m, 1H), 6.87-6.98 (m, 3H), 7.03 (td, J = 7.5, 1.1 Hz, 1H), 7.27-7.31 (m, 1H), 7.43 (d, J = 8.7 Hz, 2H), 7.67 (ddd, 1 = 12.0, 8.2, 1.4 Hz, 1H).
[0199] Intermediate 16: tert-Butyl ( / ?)-(l-{3-[(4'-hydroxy-[l,l'-biphenyl]-2-yl)oxy]propyl} azepan-3-yl)carbamate
[0200]
[0201] Colorless oil, 0.329 g (64% isolated yield); UPLC / MS purity = 97%, tR = 4.34 min; C26H35FN2O4, MW 458.57, monoisotopic mass 458.26, [M+H]+459.3.TH NMR (500 MHz, CDCI3) 6 ppm 1.44 ppm (s, 9H), 1.37-1.51 (m, 2H), 1.52-1.79 (m, 4H), 1.80-1.93 (m, 3H), 2.53-2.62 (m, 1H), 2.62-2.73 (m, 1H), 2.77-2.94 (m, 2H), 3.00 (t, J = 5.3 Hz, 2H), 3.71-3.85 (m, 1H), 4.00-4.14 (m, 2H), 6.91-6.96 (m, 2H), 6.98-7.12 (m, 3H), 7.40-7.50 (m, 2H).
[0202] Intermediate 17: tert-Butyl 6-[2-([l,l'-biphenyl]-2-yloxy)ethyl]-2,6-diazaspiro[3.4]octane-2-carboxylate
[0203] PK / 11501 / KZ
[0204]
[0205] Colorless oil, 0.405 g (91% isolated yield); UPLC / MS purity = 99%, LR = 5.65 min; C25H32N2O3, MW 408.54, monoisotopic mass 408.24, [M+H]+409.3.TH NMR (500 MHz, CDCI3) 6 ppm 1.45 (s, 9H), 1.97 (t, J = 7.1 Hz, 2H), 2.61 (s, 4H), 2.82 (s, 2H), 3.69-3.79 (m, 4H), 4.11 (t, J = 5.4 Hz, 2H), 6.96 (d, J = 8.2 Hz, 1H), 7.04 (td, J = 7.5, 1.1 Hz, 1H), 7.28-7.34 (m, 3H), 7.36-7.41 (m, 2H),
[0206] 7.48-7.52 (m, 2H).
[0207] Intermediate 18: tert-Butyl 7-{2-[(3-fluoro-4'-hydroxy-[l,l'-biphenyl]-2-yl)oxy]ethyl}-2,7-diazaspiro[3.5]nonane-2-carboxylate
[0208]
[0209] Colorless oil, 0.397 g (77% isolated yield); UPLC / MS purity = 98%, tR = 6.02 min; C26H33FN2O4, MW 456.56, monoisotopic mass 456.24, [M+H]+457.3.XH NMR (500 MHz, CDCI3) 6 ppm 1.43 (s, 9H), 1.46-1.65 (m, 4H), 2.13-2.49 (m, 4H), 2.62-2.81 (m, 2H), 3.43 (s, 4H), 4.08 (br. s., 2H), 7.05-7.10 (m, 2H), 7.33-7.37 (m, 1H), 7.39-7.43 (m, 2H), 7.50-7.53 (m, 2H).
[0210] Intermediate 19: tert-Butyl 2-[2-([l,l'-biphenyl]-2-yloxy)ethyl]-2,6-diazaspiro[3.4]octane-6-carboxylate
[0211]
[0212] PK / 11501 / KZ
[0213] Colorless oil, 0.302 g (68% isolated yield); UPLC / MS purity = 98%, tR = 6.56 min; C25H32N2O3, MW 408.53, monoisotopic mass 408.24, [M+H]+409.3.TH NMR (500 MHz, CDCI3) 6 ppm 1.45 (s, 9H), 1.85 (td, J = 7.0, 2.1 Hz, 2H), 2.67-2.73 (m, 2H), 2.81 (br. s., 2H), 3.18 (td, J = 7.0, 2.2 Hz, 2H), 3.23 (d, J = 2.2 Hz, 2H), 3.93 (td, J = 5.5, 2.2 Hz, 2H), 4.08 (m, 2H), 6.96 (d, J = 8.2 Hz, 1H), 7.04 (td, J = 7.5, 1.1 Hz, 1H), 7.28-7.34 (m, 3H), 7.36-7.41 (m, 2H), 7.48-7.52 (m, 2H).
[0214] Intermediate 20: tert-Butyl 7-{2-[(3-fluoro-[l,l'-biphenyl]-2-yl)oxy]ethyl}-2,7-diazaspiro[4.4]nonane-2-carboxylate
[0215]
[0216] Colorless oil, 0.373 g (75% isolated yield); UPLC / MS purity = 99%, tR = 5.92 min; C26H33FN2O3, MW 440.56, monoisotopic mass 440.25, [M+H]+441.2.TH NMR (500 MHz, CDCI3) 6 ppm 1.44 (s, 9H) 1.74-1.94 (m, 4H) 2.49-3.05 (m, 6H), 3.16-3.28 (m, 1H) 3.29-3.43 (m, 3H), 4.12-4.28 (m, 2H), 7.05-7.10 (m, 3H), 7.33-7.37 (m, 1H), 7.39-7.43 (m, 2H), 7.50-7.53 (m, 2H).
[0217] Intermediate 21: tert-Butyl 8-[2-([l,l'-biphenyl]-2-yloxy)ethyl]-2,8-diazaspiro[4.5]decane-2-carboxylate
[0218]
[0219] White solid, 0.350 g (78% isolated yield); UPLC / MS purity = 95%, tR = 5.92 min; C27H36N2O3, MW 436.60, monoisotopic mass 436.27, [M+H]+437.1.XH NMR (500 MHz, CDCI3) 6 ppm 1.46 (s, 9H), 1.53-1.71 (m, 6H), 2.27-2.70 (m, 4H), 2.84 (s, 2H), 3.10 (d, J = 38.8 Hz, 2H), 3.35 (dt, J = 24.9, 7.1 Hz, 2H), 4.17 (s, 2H), 7.03-7.11 (m, 1H), 7.29-7.34 (m, 3H), 7.38 (t, J = 7.5 Hz, 3H), 7.49-7.57 (m, 2H).
[0220] PK / 11501 / KZ
[0221] Intermediate 22: tert-Butyl 2-{2-[(4'-hydroxy-[l,l'-biphenyl]-2-yl)oxy]ethyl}-2,7-diazaspiro[3.5]nonane-7-carboxylate
[0222] Boc
[0223]
[0224] Colorless oil, 0.288 g (62% isolated yield); UPLC / MS purity = 98%, tR = 4.87 min; C26H34N2O4, MW 438.57, monoisotopic mass 438.25, [M+H]+439.2.XH NMR (500 MHz, CDCI3) 6 ppm 1.45 (s, 9H), 1.55-1.63 (m, 4H), 2.85 (t, J = 5.3 Hz, 2H), 2.97 (s, 4H), 3.19-3.26 (m, 4H), 4.03 (t, J = 5.4 Hz, 2H), 6.89-6.95 (m, 3H), 7.02 (td, J = 7 A, 0.9 Hz, 1H), 7.25-7.29 (m, 2H), 7.38-7.46 (m, 2H).
[0225] Intermediate 23: tert-Butyl 2-{2-[2-(furan-3-yl)phenoxy]ethyl}-2,7-diazaspiro[3.5]nonane-7-carboxylate
[0226]
[0227] Colorless oil, 0.345 g (79% isolated yield); UPLC / MS purity = 97%, LR = 5.62 min; C24H32N2O4, MW 412.53, monoisotopic mass 412.24, [M+H]+413.2.TH NMR (500 MHz, CDCI3) 6 ppm 1.44 (s, 9H), 1.58-1.62 (m, 4H), 2.82 (t, J = 5.4 Hz, 2H), 2.94 (s, 4H), 3.22-3.26 (m, 4H), 4.02 (t, J = 5.5 Hz, 2H), 6.52 (dd, J = 1.7, 1.0 Hz, 1H), 7.17-7.31 (m, 4H), 7.49 (q, J = 1.3 Hz, 2H).
[0228] Intermediate 24: tert-Butyl 2-{2-[(3-fluoro-[l,l'-biphenyl]-2-yl)oxy]ethyl}-2,7-diazaspiro[3.5]nonane-7-carboxylate
[0229] PK / 11501 / KZ
[0230]
[0231] Colorless oil, 0.345 g (74% isolated yield); UPLC / MS purity = 99%, tR = 6.53 min; C26H33FN2O3, MW 440.56, monoisotopic mass 440.25, [M+H]+441.3.TH NMR (500 MHz, CDCI3) 6 ppm 1.45 (s, 9H), 1.60-1.66 (m, 4H), 2.70 (t, J = 5.6 Hz, 2H), 2.91-3.03 (m, 4H), 3.25-3.30 (m, 4H), 3.82 (t, J = 5.5 Hz, 2H), 7.05-7.10 (m, 3H), 7.33-7.37 (m, 1H), 7.39-7.43 (m, 2H), 7.50-7.53 (m, 2H).
[0232] Intermediate 25: tert-Butyl 2-{2-[(3-fluoro-4'-hydroxy-[l,l'-biphenyl]-2-yl)oxy]ethyl}-2,7-diazaspiro[3.5]nonane-7-carboxylate
[0233]
[0234] Colorless oil, 0.335 g (65% isolated yield); UPLC / MS purity = 98%, tR = 6.00 min; C26H33FN2O4, MW 456.56, monoisotopic mass 456.24, [M+H]+457.0.XH NMR (500 MHz, CDCI3) 6 ppm 1.45
[0235] (s, 9H), 1.60-1.69 (m, 4H), 2.69 (t, J = 5.7 Hz, 2H), 2.97 (br. s., 4H), 3.23-3.36 (m, 4H), 3.79 (t, J = 5.7 Hz, 2H), 6.91-6.98 (m, 2H), 7.01-7.10 (m, 3H), 7.44-7.50 (m, 2H).
[0236] Intermediate 26: tert-Butyl 2-{2-[(3-fluoro-4'-methoxy-[l,l'-biphenyl]-2-yl)oxy]ethyl}-2,7-diazaspiro[3.5]nonane-7-carboxylate
[0237] PK / 11501 / KZ
[0238]
[0239] Colorless oil, 0.387 g (73% isolated yield); UPLC / MS purity = 99%, tR = 6.95 min; C27H35FN2O4, MW 470.59, monoisotopic mass 470.26, [M+H]+471.2.XH NMR (500 MHz, CDCI3) 6 ppm 1.45 (s, 9H), 1.62-1.67 (m, 4H), 2.63 (t, J = 5.7 Hz, 2H), 3.04 (br. s, 4H), 3.23-3.36 (m, 4H), 3.89 (t, J = 5.6 Hz, 2H), 3.79 (s, 3H), 6.91-6.98 (m, 2H), 7.01-7.10 (m, 3H), 7.44-7.50 (m, 2H).
[0240] Intermediate 27: tert-Butyl 2-{2-[(3-fluoro-4'-hydroxy-[l,l'-biphenyl]-2-yl)oxy]ethyl}-2,8-diazaspiro[4.5]decane-8-carboxylate
[0241]
[0242] Colorless oil, 0.412 g (76% isolated yield); UPLC / MS purity = 98%, tR = 5.02 min; C27H35FN2O4, MW 470.59, monoisotopic mass 470.26, [M+H]+471.2.TH NMR (500 MHz, CDCI3) 6 ppm 1.44 (s, 9H), 1.39-1.49 (m, 2H), 1.59 (dd, J = 13.4, 7.4 Hz, 4H), 2.25-2.35 (m, 2H), 2.58 (s, 2H), 2.79 (s, 2H), 2.83-2.91 (m, 2H), 2.98-3.05 (m, 2H), 4.02-4.12 (m, 2H), 6.91-6.98 (m, 2H), 7.01-7.10 (m, 3H), 7.44-7.50 (m, 2H).
[0243] Intermediate 28: tert-Butyl 2-{2-[2-fluoro-6-(pyridin-3-yl)phenoxy]ethyl}-2,8-diazaspiro[4.5]decane-8-carboxylate
[0244] PK / 11501 / KZ
[0245]
[0246] Colorless oil, 0.402 g (81% isolated yield); UPLC / MS purity = 97%, tR = 4.98 min; C26H34FN3O3, MW 455.57, monoisotopic mass 455.26, [M+H]+456.3.XH NMR (500 MHz, CDCI3) 6 ppm 1.44 (s, 9H), 1.39-1.49 (m, 2H), 1.59 (dd, J = 13.4, 7.4 Hz, 4H), 2.25-2.35 (m, 2H), 2.58 (s, 2H), 2.79 (s, 2H), 2.83-2.91 (m, 2H), 2.98-3.05 (m, 2H), 3.85 (s, 4.02-4.12 (m, 2H), 7.06 (td, J = 7.8, 1.0 Hz, 1H), 7.28-7.37 (m, 3H), 7.83 (ddd, J = 7.8, 2.3, 1.7 Hz, 1H), 8.54 (dd, J = 4.8, 1.7 Hz, 1H), 8.77 (dd, J = 2.3, 1.0 Hz, 1H).
[0247] 1.4 General procedure for the preparation of example compounds 1-19
[0248] An example reaction was carried out as follows. A solution of the selected Boc-protected intermediate 14 (0.200 g, 0.47 mmol) in a CH2CI2 / TFA mixture (4 mL, 80 / 20, v / v) was left stirring for 2 h at room temperature. After this time, the mixture was diluted with CH2CI2 (10 mL, CAS: 75-09-2), followed by the addition of 25% ammonia solution (CAS: 7664-41-7) until alkaline pH (~9) was achieved. The organic phase was separated, washed with water (2 x 5 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to furnish derivatives as a free bases. Next, the mixture of the obtained primary or secondary amine in CH2CI2 (3 mL) and TEA (3 eq., CAS: 121-44-8) was cooled and the appropriate benzenesulfonyl chloride (1.2 eq., CAS: 349-88-2) was added in one portion at 0 °C. The reaction mixture was stirred for 2 hours. The crude product was purified on a silica gel column using a CH2Cb / MeOH mixture (9 / 0.7, v / v) as an eluting system yielding Example 1. Further final example compounds 2-19 were synthesized using appropriate primary or secondary amines and selected commercially available arylsulfonyl chlorides according to the procedure described above.
[0249] Example 1: ( / ?)- / V-[(l-{3-[(3-Fluoro-4'-hydroxy-[l,l'-biphenyl]-2-yl)oxy]propyl}pyrrolidin-3-yl)methyl]benzenesulfonamide
[0250] PK / 11501 / KZ
[0251] Colorless oil, 0.092 g (62% isolated yield); UPLC / MS purity = 97%, tR = 4.68 min; C26H29FN2O4S, MW 484.59, monoisotopic mass 484.18, [M+H]+485.2.XH NMR (500 MHz, CDCI3) 6 ppm 1.48- 1.64 (m, 2H), 1.95-2.09 (m, 2H), 2.10-2.22 (m, 2H), 2.38-2.49 (m, 2H), 2.76-2.98 (m, 3H), 3.02 (t, J = 5.6 Hz, 2H), 4.19 (t, J = 5.6 Hz, 2H), 4.98 (br. s., 1H), 6.90-6.95 (m, 2H), 6.98-7.12 (m, 3H), 7.28-7.31 (m, 2H), 7.40-7.50 (m, 2H), 7.54-7.59 (m, 1H), 7.89-7.93 (m, 2H).
[0252] Example 2: 3-Chloro- / V-(l-{3-[(4'-hydroxy-[l,l'-biphenyl]-2-yl)oxy]propyl}piperidin-4-yl)benzenesulfonamide
[0253] White solid, 0.123 g (80% isolated yield); UPLC / MS purity = 100%, tR = 5.23 min; C26H29CIN2O4S, MW 501.04, monoisotopic mass 500.15, [M+H]+501.3.TH NMR (500 MHz, CDCI3) 6 ppm 1.84-2.09 (m, 6H), 2.72 (t, J = 7.9 Hz, 2H), 3.02 (s, 2H), 3.35 (d, J = 3.9 Hz, 2H), 3.49 (s, 1H), 3.93 (t, J = 5.5 Hz, 2H), 6.63-7.08 (m, 5H), 7.20-7.34 (m, 3H), 7.45 (t, J = 7.9 Hz, 1H), 7.53 (ddd, J = 8.1, 2.1, 1.1 Hz, 1H), 7.81 (dt, J = 7.9, 1.4 Hz, 1H), 7.91 (t, J = 1.9 Hz, 1H).
[0254] Example 3: 4-Fluoro- / V-(l-{3-[(4'-hydroxy-[l,l'-biphenyl]-2-yl)oxy]propyl}piperidin-4-yl)benzenesulfonamide
[0255] White solid, 0.121 g (81% isolated yield); UPLC / MS purity = 100% tR= 4.89 min; C26H29FN2O4S, MW 484.59, monoisotopic mass 484.18, [M+H]+485.3.TH NMR (500 MHz, CDCI3) 6 ppm 1.77-2.07 (m, 6H), 2.67 (t, J = 7.8 Hz, 2H), 2.97 (s, 2H), 3.22-3.37 (m, 1H), 3.49 (s, 1H), 3.92 (t, J = 5.6 Hz, 2H), 6.89 (dd, J = 8.3, 1.1 Hz, 1H), 6.95 (d, J = 8.3 Hz, 2H), 7.01 (td, J = 7 A, 1.1 Hz, 1H), 7.13-7.20 (m, 2H), 7.20-7.28 (m, 4H), 7.30-7.35 (m, 2H), 7.87-7.97 (m, 2H).
[0256] Example 4: / V-(l-{3-[(4'-Hydroxy-[l,l'-biphenyl]-2-yl)oxy]propyl}piperidin-4-yl)-4-methylbenzenesulfonamide
[0257] White solid, 0.115 g (77% isolated yield); UPLC / MS purity = 99%, tR= 5.35 min; C27H32N2O4S, MW 480.62, monoisotopic mass 480.21, [M+H]+481.2.TH NMR (500 MHz, CDCI3) 6 ppm 1.53- 1.65 (m, 2H), 1.73-1.84 (m, 2H), 1.86-1.96 (m, 2H), 2.07-2.26 (m, 2H), 2.42 (s, 3H), 2.48 (t, J = 7.8 Hz, 2H), 2.68-2.78 (m, 2H), 3.18 (d, J = 4.4 Hz, 1H), 3.93 (t, J = 5.8 Hz, 2H), 5.02 (s, 1H), 6.81-6.90 (m, 2H), 6.90 (dd, J = 8.2, 1.1 Hz, 1H), 7.00 (td, J = 7.5, 1.1 Hz, 1H), 7.24 (td, J = 7.8, 1.8 Hz, 1H), 7.26-7.33 (m, 3H), 7.31-7.40 (m, 2H), 7.73-7.80 (m, 2H).
[0258] PK / 11501 / KZ
[0259] Example 5: / V-(l-{3-[(3-Fluoro-4'-hydroxy-[l,l'-biphenyl]-2-yl)oxy]propyl}piperidin-4-yl) benzenesulfonamide
[0260] Colorless oil, 0.108 g (77% isolated yield); UPLC / MS purity = 97%, tR = 5.64 min; C26H29FN2O4S, MW 484.59, monoisotopic mass 484.18, [M+H]+485.0.XH NMR (500 MHz, CDCI3) 6 ppm 1.74-1.97 (m, 6H), 2.43 (t, J = 8.0 Hz, 4H), 2.81-2.95 (m, 2H), 3.26-3.33 (m, 1H), 3.82 (t, J = 5.5 Hz, 2H), 6.96 (d, J = 8.3 Hz, 2H), 7.01-7.06 (m, 3H), 7.28-7.31 (m, 2H), 7.47-7.52 (m, 2H), 7.54-7.59 (m, 1H), 7.89-7.93 (m, 2H).
[0261] Example 6: ( / ?)- / V-(l-{3-[(3-Fluoro-4'-hydroxy-[l,l'-biphenyl]-2-yl]oxy]propyl}azepan-4-yl)benzenesulfonamide
[0262] Colorless oil, 0.093 g (64% isolated yield); UPLC / MS purity = 98%, tR = 5.87 min; C27H31FN2O4S, MW 498.20, monoisotopic mass 498.20, [M+H]+499.3.TH NMR (500 MHz, CDCI3) 6 ppm 1.37-1.51 (m, 2H), 1.52-1.79 (m, 4H), 1.80-1.93 (m, 3H), 2.53-2.62 (m, 1H), 2.62-2.73 (m, 1H), 2.77-2.94 (m, 2H), 3.00 (t, J = 5.3 Hz, 2H), 3.71-3.85 (m, 1H), 4.00-4.14 (m, 2H), 6.91-6.96 (m, 2H), 6.98-7.12 (m, 3H), 7.40-7.50 (m, 2H). 7.49-7.53 (m, 2H), 7.55-7.59 (m, 1H), 7.87-7.90 (m, 2H).
[0263] Example 7: 6-[2-([l,l'-Biphenyl]-2-yloxy)ethyl]-2-[(4-fluorophenyl)sulfonyl]-2,6-diazaspiro[3.4]octane
[0264] White solid, 0.098 g (65% isolated yield); UPLC / MS purity = 96%, tR= 5.51 min; C26H27FN2O3S, MW 466.57, monoisotopic mass 466.17, [M+H]+467.1.TH NMR (500 MHz, CDCI3) 6 ppm 1.77-1.82 (m, 2H), 2.54 (br. s., 4H), 2.81 (br. s., 2H), 3.53-3.66 (m, 4H), 4.08 (br. s., 2H), 6.93 (d, J = 8.0 Hz, 1H), 7.05 (td, J = 7.5, 1.1 Hz, 1H), 7.19-7.30 (m, 2H), 7.25-7.35 (m, 3H), 7.31-7.41 (m, 2H), 7.42-7.51 (m, 2H), 7.79-7.89 (m, 2H).
[0265] Example 8: 3'-Fluoro-2'-{2-[2-(phenylsulfonyl)-2,7-diazaspiro[3.5]nonan-7-yl]ethoxy}-[l,l'-biphenyl]-4-ol
[0266] White solid, 0.086 g (62% isolated yield); UPLC / MS purity = 95%, tR = 6.41 min; C27H29FN2O4S, MW 496.60, monoisotopic mass 496.18, [M+H]+497.1.TH NMR (500 MHz, CDCI3) 6 ppm 1.50-1.65 (m, 4H), 2.12-2.47 (m, 4H), 2.68 (br. s., 2H), 3.46 (s, 4H), 3.95 (br. s., 2H), 6.85-6.89 (m,PK / 11501 / KZ
[0267] 2H), 7.01-7.08 (m, 3H), 7.31-7.35 (m, 2H), 7.57-7.62 (m, 2H), 7.63-7.69 (m, 1H), 7.83-7.87 (m, 2H).
[0268] Example 9: 2-[2-([l,l'-Biphenyl]-2-yloxy)ethyl]-6-[(4-fluorophenyl)sulfonyl]-2,6-diazaspiro[3.4]octane
[0269] White solid, 0.095 (63% isolated yield); UPLC / MS purity = 99%, tR= 5.62 min; C26H27FN2O3S, MW 466.57, monoisotopic mass 466.17, [M+H]+467.1.XH NMR (500 MHz, CDCI3) 6 ppm 1.85 (td, J = 7.0, 2.1 Hz, 2H), 2.67-2.73 (m, 2H), 2.81 (br. s., 2H), 3.18 (td, J = 7.0, 2.2 Hz, 2H), 3.23 (d, J = 2.2 Hz, 2H), 3.93 (td, J = 5.5, 2.2 Hz, 2H), 4.08 (m, 2H), 6.89-6.93 (m, 1H), 7.03 (td, J = 7.5, 2.1 Hz, 1H), 7.20 (td, J = 8.6, 2.2 Hz, 2H), 7.25-7.31 (m, 3H), 7.34 (td, J = 8.1, 7.7, 2.1 Hz, 2H), 7.43-7.48 (m, 2H), 7.78-7.86 (m, 2H).
[0270] Example 10: 2-{2-[(3-Fluoro-[l,l'-biphenyl]-2-yl)oxy]ethyl}-7-(phenylsulfonyl)-2,7-diazaspiro[4.4]nonane
[0271] White solid, 0.085 g (60% isolated yield); UPLC / MS purity = 96%, tR= 6.24 min; C27H29FN2O3S, MW 480.60, monoisotopic mass 480.19, [M+H]+481.6.TH NMR (500 MHz, CDCI3) 6 ppm 1.47-1.62 (m, 2H), 1.67-1.84 (m, 2H), 2.08-2.38 (m, 2H), 2.40-2.86 (m, 4H), 3.13 (q, J = 9.8 Hz, 2H), 3.21-3.38 (m, 2H), 3.88 (br. s., 2H), 7.07-7.11 (m, 3H), 7.32-7.36 (m, 1H), 7.38-7.42 (m, 2H), 7.47-7.53 (m, 4H), 7.54-7.58 (m, 1H), 7.81-7.85 (m, 2H).
[0272] Example 11: 8-[2-([l,l'-Biphenyl]-2-yloxy)ethyl]-2-[(4-fluorophenyl)sulfonyl]-2,8-diazaspiro[4.5]decane
[0273] White solid, 0.111 g (76% isolated yield); UPLC / MS purity = 97%, tR= 5.77 min; C28H31FN2O3S, MW 494.63, monoisotopic mass 494.20, [M+H]+495.1.TH NMR (500 MHz, CDCI3) 6 ppm 1.34-1.51 (m, 4H), 1.59 (t, J = 6.9 Hz, 3H), 2.04 (s, 1H), 2.26-2.63 (m, 2H), 2.79-2.94 (m, 2H), 3.00 (d, J = 4.8 Hz, 2H), 3.25 (t, J = 7.2 Hz, 2H), 4.09-4.15 (m, 1H), 4.19 (br. s„ 1H), 6.95 (dd, J = 8.7, 0.9 Hz, 1H), 7.06 (t, J = 7.2 Hz, 1H), 7.19-7.24 (m, 2H), 7.31 (td, J = 7.3, 1.7 Hz, 3H), 7.37 (t, J = 7.5 Hz, 2H), 7.48 (d, J = 7.4 Hz, 2H), 7.81-7.86 (m, 2H).
[0274] Example 12: 2'-(2-{7-[(4-Fluorophenyl)sulfonyl]-2,7-diazaspiro[3.5]nonan-2-yl}ethoxy)-[l,l'-biphenyl]-4-ol
[0275] PK / 11501 / KZ
[0276] White solid, 0.099 g (68% isolated yield); UPLC / MS purity = 98%, tR= 5.07 min; C27H29FN2O4S, MW 496.60, monoisotopic mass 496.18, [M+H]+497.2.XH NMR (500 MHz, CDCI3) 6 ppm 1.73 (t, J = 5.6 Hz, 4H), 2.87 (t, J = 5.4 Hz, 6H), 2.97 (s, 4H), 4.01 (t, J = 5.0 Hz, 2H), 6.67-6.80 (m, 2H),
[0277] 6.86 (dd, J = 8.6, 1.1 Hz, 1H), 7.00 (td, J = 7.5, 1.1 Hz, 1H), 7.18-7.27 (m, 6H), 7.74-7.82 (m, 2H).13C NMR (126 MHz, CDCI3) 6 ppm 34.1, 34.9, 43.1, 53.6, 64.3, 67.1, 112.4, 115.0, 116.5, 116.7, 121.4, 128.4, 130.5, 130.6, 130.8, 131.1, 132.6, 132.6, 155.5, 155.6, 164.4, 166.4.
[0278] Example 13: 7-[(4-Fluorophenyl)sulfonyl]-2-{2-[2-(furan-3-yl)phenoxy]ethyl}-2,7-diazaspiro[3.5]nonane
[0279] White solid, 0.108 g (72% isolated yield); UPLC / MS purity = 100%, tR= 5.50 min; C25H27FN2O4S, MW 470.56, monoisotopic mass 470.17, [M+H]+471.2.TH NMR (500 MHz, CDCI3) 6 ppm 1.75-1.89 (m, 4H), 2.88 (t, J = 5.8 Hz, 2H), 2.93 (t, J = 5.6 Hz, 4H), 2.99 (s, 4H), 3.99 (t, J = 5.8 Hz, 2H), 6.77 (d, J = 1.8 Hz, 1H), 6.89 (dd, J = 8.2, 1.1 Hz, 1H), 6.98 (td, J = 7.5, 1.1 Hz, 1H), 7.14-7.24 (m, 3H), 7.40 (t, J = 1.7 Hz, 1H), 7.47 (dd, J = 7.6, 1.7 Hz, 1H), 7.72-7.77 (m, 2H), 8.10 (t, J = 1.1 Hz, 1H).
[0280] Example 14: 2-{2-[(3-Fluoro-[l,l'-biphenyl]-2-yl)oxy]ethyl}-7-(phenylsulfonyl)-2,7-diazaspiro[3.5]nonane
[0281] White solid, 0.110 g (78% isolated yield); UPLC / MS purity = 100%, tR= 6.38 min; C27H29FN2O3S, MW 480.60, monoisotopic mass 480.19, [M+ H]+481.1.TH NMR (500 MHz, CDCI3) 6 ppm 1.76 (t, J = 5.6 Hz, 4H), 2.67 (t, J = 5.3 Hz, 2H), 2.85-2.93 (m, 8H), 3.82 (t, J = 5.3 Hz, 2H), 7.02-7.07 (m, 3H), 7.20-7.24 (m, 1H), 7.28-7.33 (m, 2H), 7.42-7.45 (m, 2H), 7.54-7.58 (m, 2H), 7.60-7.65 (m, 1H), 7.74-7.78 (m, 2H).
[0282] Example 15: 2-{2-[(3-Fluoro-4'-methoxy-[l,l'-biphenyl]-2-yl)oxy]ethyl}-7-(phenylsulfonyl)-2,7-diazaspiro[3.5]nonane
[0283] White solid, 0.109 g (79% isolated yield); UPLC / MS purity = 95%, tR= 6.41 min; C28H31FN2O4S, MW 510.62, monoisotopic mass 510.20, [M+H]+511.2.TH NMR (500 MHz, CDCI3) 6 ppm 1.72- 1.86 (m, 4H), 2.60 (t, J = 5.5 Hz, 2H), 2.84 (s, 4H), 2.92 (t, J = 5.6 Hz, 4H), 3.72 (t, J = 5.5 Hz, 2H), 3.83 (s, 3H), 6.87-6.92 (m, 2H), 6.99-7.07 (m, 3H), 7.40-7.45 (m, 2H), 7.52-7.56 (m, 2H), 7.58-7.63 (m, 1H), 7.72-7.78 (m, 2H).
[0284] PK / 11501 / KZ
[0285] Example 16: 2-{2-[(3-Fluoro-4'-methoxy-[l,l'-biphenyl]-2-yl)oxy]ethyl}-7-[(4-fluorophenyl)sulfonyl]-2,7-diazaspiro[3.5] nonane
[0286] White solid, 0.096 g (66% isolated yield); UPLC / MS purity = 99%, tR= 6.84 min; C28H30F2N2O4S, MW 528.61, monoisotopic mass 528.19, [M+H]+528.2.XH NMR (500 MHz, CDCI3) 6 ppm 1.78 (t, J = 5.6 Hz, 4H), 2.61 (t, J = 5.6 Hz, 2H), 2.85 (s, 4H), 2.91 (t, J = 5.6 Hz, 4H), 3.72 (t, J = 5.6 Hz, 2H), 3.84 (s, 3H), 6.87-6.92 (m, 2H), 6.99-7.07 (m, 3H), 7.19-7.24 (m, 2H), 7.41-7.45 (m, 2H), 7.73-7.79 (m, 2H).
[0287] Example 17: 2-{2-[(3-Fluoro-[l,l'-biphenyl]-2-yl)oxy]ethyl}-8-(phenylsulfonyl)-2,8-diazaspiro[4.5]decane
[0288] White solid, 0.120 g (86% isolated yield); UPLC / MS purity = 99%, tR= 6.38 min; C28H31FN2O3S, MW 494.63, monoisotopic mass 494.20, [M+H]+495.0.TH NMR (500 MHz, CDCI3) 6 ppm 1.47-1.54 (m, 2H), 1.58-1.69 (m, 4H), 2.27-2.46 (m, 2H), 2.62 (br. s., 2H), 2.71 (s, 2H), 2.88-3.05 (m, 4H), 3.92 (br. s., 2H), 7.03-7.10 (m, 3H), 7.30-7.34 (m, 1H), 7.35-7.40 (m, 2H), 7.45-7.48 (m, 2H), 7.52-7.56 (m, 2H), 7.58-7.63 (m, 1H), 7.74-7.76 (m, 1H), 7.76 (s, 1H).
[0289] Example 18: 3'-Fluoro-2'-{2-[8-(phenylsulfonyl)-2,8-diazaspiro[4.5]decan-2-yl]ethoxy}-[l,l'-biphenyl]-4-ol
[0290] White solid, 0.112 g (84% isolated yield); UPLC / MS purity = 100%, tR= 5.89 min; C28H31FN2O4S, MW 510.62, monoisotopic mass 510.20, [M+H]+511.0.TH NMR (500 MHz, CDCI3) 6 ppm 1.54 (t, J = 6.9 Hz, 2H), 1.57-1.69 (m, 4H), 2.40-2.46 (m, 2H), 2.66-2.82 (m, 4H), 2.90 (ddd, J = 11.8, 7.6, 4.0 Hz, 2H), 3.03 (ddd, J = 11.4, 6.7, 4.1 Hz, 2H), 3.92 (t, J = 5.4 Hz, 2H), 6.82 (d, J = 8.6 Hz, 2H), 6.96-7.09 (m, 3H), 7.28-7.37 (m, 2H), 7.53 (dd, J = 8.3, 6.8 Hz, 2H), 7.55-7.65 (m, 1H), 7.71-7.80 (m, 2H).
[0291] Example 19: 2-{2-[2-Fluoro-6-(pyridin-3-yl)phenoxy]ethyl}-8-(phenylsulfonyl)-2,8-diazaspiro[4.5]decane
[0292] Yellow solid, 0.114 g (82% isolated yield); UPLC / MS purity = 100%, tR= 4.90 min; C27H30FN3O3S, MW 495.61, monoisotopic mass 495.20, [M+H]+496.2.TH NMR (500 MHz, CDCI3) 6 ppm 1.54 (t, J = 6.9 Hz, 2H), 1.57-1.69 (m, 4H), 2.40-2.46 (m, 2H), 2.66-2.82 (m, 4H), 2.90 (ddd, J = 11.8, 7.6, 4.0 Hz, 2H), 3.03 (ddd, J = 11.4, 6.7, 4.1 Hz, 2H), 3.92 (t, J = 5.4 Hz, 2H), 7.03-7.14 (m, 3H),PK / 11501 / KZ
[0293] 7.22-7.30 (m, 1H), 7.54 (ddt, J = 8.4, 6.6, 1.4 Hz, 2H), 7.56-7.65 (m, 1H), 7.70-7.79 (m, 2H), 7.81 (dt, J = 7.8, 2.0 Hz, 1H), 8.47 (dd, J = 4.8, 1.7 Hz, 1H), 8.72 (d, J = 2.3 Hz, 1H).
[0294] Assessment of the affinity of compounds using the specific radioligand displacement method in in vitro binding assays and assessment of functional in vitro activity at 5-HT? receptor The compounds of the invention have been tested using verified experimental methods as commonly used in the art. The affinity of the compounds of the invention towards the 5-HT? receptor was assessed by measuring the inhibition of binding of the radioactive ligand ( [3H]-5-CT) binding to the 5-HT? receptor as described in the assay. The experiments were carried out according to previously published protocols (Kurczab et al. 2018) using HEK293 (ATCC) cell line with stable expression of the human 5-HT?b receptor (prepared with the use of Lipofectamine 2000). Experimental assays were carried out in uniform volumes of 200 pL on 96-well plates for 1 h at 37 °C. Equilibration was terminated by rapid filtration using GF / C UniFilter plates (PerkinElmer, USA) with a 96-well cell harvester and the radioactivity retained on the filters was quantified using a Microbeta plate reader (PerkinElmer, USA). The test samples in the displacement assays contained 0.8 nM [3H]-5-CT (39.2 Ci / mmol, PerkinElmer, USA) as the radioligand. Nonspecific binding was assessed in 5-HT? receptor binding experiments in the presence of 10 pM 5-HT. Each compound was tested at 7 different concentrations ranging from 10“10to 10“4M. Inhibition constants ( i) were calculated from the Cheng-Prusoff equation. The results are shown in Table 1 below.
[0295] The inverse agonist properties at the 5-HT? receptor according to the invention were assessed by measuring the inhibition of the production of cAMP in transiently transfected HEK293T cells expressing the human 5-HT?a receptor and the cAMP GloSensor-22F as described in the assay (Lewis et al. Cell Reports 2023).
[0296] The affinity towards 5-HTIA and dopamine DZL receptors was determined using HEK293 cell line with stable expression of human 5-HTIA and DZL receptors (prepared with the use of Lipofectamine 2000), according to previously published protocols (Vanda et al. 2021). For the displacements assays, the test specimens contained the following radioligands (PerkinElmer, USA): 2.5 nM [3H]-8-OH-DPAT (135.2 Ci / mmol) for the 5-HTIA receptor affinity assay and 2.5 nM [3H]-raclopride (76.0 Ci / mmol) for the DZL receptor affinity assay. Nonspecific binding was assessed in the presence of 10 pM 5-HT in 5-HTIA receptor binding experiments and in thePK / 11501 / KZ
[0297] presence of 10 pM haloperidol in D21. receptor binding experiments. Each compound was tested at 7 different concentrations ranging from 1O“10to 10“4M. Inhibition constants (K) were calculated from the Cheng-Prusoff equation.
[0298] Table 1. Binding of representative compounds to 5-HT7, 5-HTIA, and D2 receptors.
[0299]
[0300] aMean values of K (SEM < 15%) based on three independent binding experiments.
[0301] The preferred compounds of the present invention have an affinity towards the 5-HT? receptor
[0302] (K) of below 50 nM as measured in the assay disclosed above. Compounds of particular interest demonstrate the affinity towards the 5-HT? receptor of below 10 nM. Compounds of particular interest exhibit a more than 50-fold greater selectivity compared to the 5-HTIA receptor and the dopamine D2 receptor.
[0303] In addition, the compounds of the present invention exhibit the characteristics of inverse agonists of the 5-HT? receptor (range 3.18-64.6 nM), with several compounds exhibiting potent activity (IC50 < 10 nM), with many of them (examples 3, 5, 12, 17) exhibiting potency comparable to that of the reference SB-266970 compound. The results are shown in Table 2 below.
[0304] Table 2. IC50 and pICso values of selected examples and reference drugs
[0305]
[0306] PK / 11501 / KZ
[0307]
[0308] aInverse agonism towards human 5-HT7areceptor was measured by the Giosensor cAMP assay evaluated after incubation for 180-210 min. A positive 5-HT control was used to show agonist activity with EC5o = 2.54 nM, pEC5o = 8.60. The data represent averages from at least two independent assays.
[0309] 2. Experimental procedure to assess metabolic stability using rat liver microsomes
[0310] The metabolic stability of the compounds was assessed in accordance with the previously described procedures (Canale et al. 2022). Solutions of test compounds at final concentration of 10 pM were preincubated in phosphate buffer (pH = 7.4) containing rat liver microsomes (0.5 mg / mL) for 10 min at 37 °C. The reaction was initiated by adding a NADPH-regenerating system and incubated for 0, 30, and 60 min at 37 °C. The reaction was terminated by the addition of ice-cold methanolic solution of the internal standard (pentoxifylline, 100 nM). Samples were then centrifuged and the supernatants were subjected to UPLC / MS analysis. All experiments were conducted in duplicate. The half-life (ti / 2) was determined from the slope of the line of Ln plots (% of the remaining parent compounds as a function of time). Clint was calculated from the following equation: Clint = [incubation volume (pL) / protein quantity (mg) x 0.693] / ti / 2. The yield of the assay was confirmed using imipramine, an extensively metabolized drug, as a reference compound.
[0311] The results are shown in Table 3 below.
[0312] Table 3. Metabolic stability of selected examples and reference drugs.
[0313]
[0314] aDetermined in the RLM assay at protein concentration of 0.5 mg / mL.The results are averages from two independent experiments carried out in duplicates.
[0315] Consequently, since the compounds of the invention were shown to demonstrate affinity in the assays described above, they are considered useful in the treatment of affective disorders, e.g., depression, anxiety disorder, panic disorder, obsessive-compulsive disorder, attention-
[0316] PK / 11501 / KZ
[0317] deficit hyperactivity disorder, autism spectrum disorder, schizophrenia, as well as in the treatment of diseases related to neurodegeneration, pain or irritable bowel syndrome.
[0318] References:
[0319] 1. Andressen, K.W.; Norum, J.H.; Levy, F.O.; Krobert, K.A. Mol. Pharmacol. 2006, 69, 207-215.
[0320] 2. Canale, V.; Kurczab, R.; Partyka, A.; Satala, G.; Lenda, T.; Jastrz^bska-Wi^sek, M.;
[0321] Wesotowska, A.; Bojarski, A.J.; Zajdel, P. Eur. J. Med. Chem. 2016, 108, 334-346.
[0322] 3. Canale, V.; Partyka, A.; Kurczab, R.; Krawczyk, M.; Kos, T.; Satala, G.; Kubica, B.; Jastrz^bska- Wi^sek, M.; Wesotowska, A.; Bojarski, A.J.; Popik, R; Zajdel, P. Bioorg. Med. Chem. 2017, 25, 2789-2799.
[0323] 4. Canale, V.; Trybata, W.; Chaumont-Dubel, S.; Koczurkiewicz-Adamczyk, P.; Satata, G.;
[0324] Bento, O.; Blicharz-Futera, K.; Bantreil, X.; P^kala, E.; Bojarski, A.J.; Lamaty, F.; Marin, P.; Zajdel, P. Biomolecules 2022, 13, 12.
[0325] 5. De Deurwaerdere, P.; Bharatiya, R.; Chagraoui, A.; Di Giovanni, G. Neuropharmacol. 2020,
[0326] 168, 107967.
[0327] 6. Gottlieb, N.; Li, T.Y.; Young, A.H.; Stokes, P.R. J. Psychopharmacol. 2023, 37, 1167-1181.
[0328] 7. Hagan, J.J.; Price, G.W.; Jeffrey, P.; Deeks, N.J.; Stean, T.; Piper, D.; Smith, M.L; Upton, N.;
[0329] Medhurst, A.D.; Middlemiss, D.N.; Riley, G.J.; Lovell, P.J.; Bromidge, S.M.; Thomas, D.R. Br. J. Pharmacol. 2000, 130, 539-548.
[0330] 8. Lewis, V.; Bonniwell, E.M.; Ghaffari, A.; Sheshbaradaran, H.; Cao, A.B.; Calkins, M.M.;
[0331] Bautista-Carro, M.A.; Arsenault, E.;Telfer, A.; Taghavi-Abkuh, F-F.; Malcolm, N.J.; El Sayegh, F.; Abizaid, A.; Schmid, Y.; Morton, K.; Halberstadt, A.L.; Aguilar-Valles, A.; McCorvy, J.D. Cell Rep. 2023, 42, 112203.
[0332] 9. Lovenberg, T.W.; Baron, B.M.; de Lecea, L.; Miller, J.D.; Prosser, R.A.; Rea, M.A.; Foye, P.E.;
[0333] Racke, M.; Slone, A.L.; Siegel, B.W.; Danielson, P.E.; Sutcliffe, J.G.; Erlander, M.G. Neuron.
[0334] 1993, 11, 449-458.
[0335] 10. Kotaczkowski, M.; Marcinkowska, M.; Bucki, A.; Pawtowski, M.; Krukowski, A.; Rusiecki, R.;
[0336] Siwek, A.; Wolak, M. US20140135310.
[0337] 11. Kurczab, R.; Canale, V.; Satata, G.; Zajdel, P.; Bojarski, AJ. J. Med. Chem. 2018, 61, 8717-PK / 11501 / KZ
[0338] 12. Vanda, D.; Canale, V.; Chaumont-Dubel, S.; Kurczab, R.; Satata, G.; Koczurkiewicz- Adamczyk, P.; Krawczyk, M.; Pietrus, W.; Blicharz, K.; P^kala, E.; Bojarski, A.J.; Popik, P.; Marin, R; Soural, M.; Zajdel, P. J. Med. Chem. 2021, 64, 1180-1196.
[0339] 13. Zajdel, P.; Kurczab, R.; Grychowska, K.; Satata, G.; Pawtowski, M.; Bojarski, AJ. Eur. J. Med.
[0340] Chem. 2012, 56, 348-360.
[0341] 14. Zajdel, P.; Canale, V; Partyka, A.; Marciniec, K.; Kurczab, R.; Satata, G.; Siwek, A.;
[0342] Jastrz^bska-Wi^sek, M.; Wesotowska, A.; Kos, T.; Popik, P.; Bojarski, AJ. Med. Chem. Commun. 2015, 6, 1272-1277.
Claims
PK / 11501 / KZClaims1. A compound of general Formula (I):wherein:- Z is an aryl or heteroaryl substituted with group(s) selected from methoxyl, hydroxyl, and / or halogen, wherein heteroaryl is selected from 5- or 6-membered heteroaryl rings comprising a heteroatom selected from N or O;- Ri is hydrogen or fluorine;- n is 2 or 3,- R2 is hydrogen, halogen, or methyl;- A is an alicyclic diamine of general Formula Gl, G2, G3, or G4:wherein k = 0 or 1; I = 0, 1, or 2; and m = 1 or 2;or a pharmaceutically acceptable salt thereof.
2. Compound according to claim 1 characterized in that A corresponds to a substructure of general Formula Gl,PK / 11501 / KZwherein k = 1, 1 = 0, m = 1, or wherein k = 0, 1 = 0, m = 2, or wherein k = 0, 1 = 1, m = 1, or wherein k = 1, 1 = 2, m = 1, the most preferably wherein k = 0, 1= 1, m = 1.
3. Compound according to claim 1 characterized in that A corresponds to a substructure of general Formula G2,G2wherein I = 1 and m = 2, or wherein I = 2 and m = 2, preferably wherein I = 2 and m = 2.
4. Compound according to claim 1 characterized in that A corresponds to a substructure of general Formula G3,G3wherein I = 1 and m = 1, or wherein I = 1 and m = 2, or wherein I = 2 and m = 2, preferably wherein I = 2 and m = 2.
5. Compound according to claim 1 characterized in that A corresponds to a substructure of general Formula G4,PK / 11501 / KZG4wherein I = 1 and m = 1, or wherein I = 1 and m = 2, preferably wherein I = 1 and m = 2.
6. Compound according to any one of claims 1 to 5, characterized in that said compound is selected from:( / ?)- / V-[(l-{3-[(3-Fluoro-4'-hydroxy-[l,l'-biphenyl]-2-yl)oxy]propyl}pyrrolidin-3-yl)methyl] benzenesulfonamide;3-Chloro- / V-(l-{3-[(4'-hydroxy-[l,l'-biphenyl]-2-yl)oxy]propyl)piperidin-4-yl}benzenesulfonamide;4-Fluoro- / V-(l-{3-[(4'-hydroxy-[l,l'-biphenyl]-2-yl)oxy]propyl}piperidin-4-yl)benzenesulfonamide; / V-(l-{3-[(4'-Hydroxy-[l,l'-biphenyl]-2-yl)oxy]propyl}piperidin-4-yl)-4-methylbenzenesulfonamide; / V-(l-{3-[(3-Fluoro-4'-hydroxy-[l,l'-biphenyl]-2-yl)oxy]propyl}piperidin-4-yl)benzenesulfonamide;( / ?)- / V-(l-{3-[(3-Fluoro-4'-hydroxy-[l,l'-biphenyl]-2-yl)oxy]propyl}azepan-4-yl)benzenesulfonamide;6-[2-([l,l'-Biphenyl]-2-yloxy)ethyl]-2-[(4-fluorophenyl)sulfonyl]-2,6-diazaspiro[3.4]octane;3'-Fluoro-2'-{2-[2-(phenylsulfonyl)-2,7-diazaspiro[3.5]nonan-7-yl]ethoxy}-[l,l'-biphenyl]-4-ol;2-[2-([l,l'-Biphenyl]-2-yloxy)ethyl]-6-[(4-fluorophenyl)sulfonyl]-2,6-diazaspiro[3.4]octane;2-{2-[(3-Fluoro-[l,l'-biphenyl]-2-yl)oxy]ethyl}-7-(phenylsulfonyl)-2,7-diazaspiro[4.4]nonane;8-[2-([l,l'-Biphenyl]-2-yloxy)ethyl]-2-[(4-fluorophenyl)sulfonyl]-2,8-diazaspiro[4.5]decane;PK / 11501 / KZ2'-(2-{7-[(4-Fluorophenyl)sulfonyl]-2,7-diazaspiro[3.5]nonan-2-yl}ethoxy)-[l,l'-biphenyl]-4-ol;7-[(4-Fluorophenyl)sulfonyl]-2-{2-[2-(furan-3-yl)phenoxy]ethyl}-2,7-diazaspiro[3.5]nonane;2-{2-[(3-Fluoro-[l,l'-biphenyl]-2-yl)oxy]ethyl}-7-(phenylsulfonyl)-2,7-diazaspiro[3.5]nonane;2-{2-[(3-Fluoro-4'-methoxy-[l,l'-biphenyl]-2-yl)oxy]ethyl}-7-(phenylsulfonyl)-2,7-diazaspiro[3.5]nonane;2-{2-[(3-Fluoro-4'-methoxy-[l,l'-biphenyl]-2-yl)oxy]ethyl}-7-[(4-fluorophenyl)sulfonyl]-2,7-diazaspiro[3.5]nonane;2-{2-[(3-Fluoro-[l,l'-biphenyl]-2-yl)oxy]ethyl}-8-(phenylsulfonyl)-2,8-diazaspiro[4.5]decane;3'-Fluoro-2'-{2-[8-(phenylsulfonyl)-2,8-diazaspiro[4.5]decan-2-yl]ethoxy}-[l,l'-biphenyl]-4-ol;2-{2-[2-Fluoro-6-(pyridin-3-yl)phenoxy]ethyl}-8-(phenylsulfonyl)-2,8-diazaspiro[4.5]decane.
7. The compound of any of the preceding claims, selected from:3-Chloro- / V-(l-{3-[(4'-hydroxy-[l,l'-biphenyl]-2-yl)oxy]propyl)piperidin-4-yl}benzenesulfonamide;4-Fluoro- / V-(l-{3-[(4'-hydroxy-[l,l'-biphenyl]-2-yl)oxy]propyl}piperidin-4-yl)benzenesulfonamide; / V-(l-{3-[(3-Fluoro-4'-hydroxy-[l,l'-biphenyl]-2-yl)oxy]propyl}piperidin-4-yl)benzenesulfonamide;2-{2-[(3-Fluoro-[l,l'-biphenyl]-2-yl)oxy]ethyl}-7-(phenylsulfonyl)-2,7-diazaspiro[3.5]nonane;2-{2-[(3-Fluoro-4'-methoxy-[l,l'-biphenyl]-2-yl)oxy]ethyl}-7-(phenylsulfonyl)-2,7-diazaspiro[3.5]nonane;2-{2-[(3-Fluoro-4'-methoxy-[l,l'-biphenyl]-2-yl)oxy]ethyl}-7-[(4-fluorophenyl)sulfonyl]-2,7-diazaspiro[3.5]nonane;2-{2-[(3-Fluoro-[l,l'-biphenyl]-2-yl)oxy]ethyl}-8-(phenylsulfonyl)-2,8-diazaspiro[4.5]decane;3'-Fluoro-2'-{2-[8-(phenylsulfonyl)-2,8-diazaspiro[4.5]decan-2-yl]ethoxy}-[l,l'-biphenyl]-4-ol;PK / 11501 / KZor pharmaceutically acceptable salts thereof.
8. Pharmaceutical composition comprising a compound according to claims 1-7 or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier or diluent.
9. Compound according to claims 1-7 or a pharmaceutically acceptable salt thereof for the preparation of a medicament to be used in the treatment of disorders or conditions resulting from the disturbance of 5-HT? receptor-dependent signaling transmission such as depression, anxiety disorder, panic disorder, obsessive-compulsive disorder, attention deficit hyperactivity disorder, autism spectrum disorder, schizophrenia, as well as in the treatment of diseases related to neurodegeneration, pain or irritable bowel syndrome.
10. Compound according to claims 1-7 or a pharmaceutically acceptable salt thereof for administration in a therapeutically effective amount for the treatment of disorders or conditions resulting from the disturbance of 5-HT? receptor-dependent signaling transmission such as depression, anxiety disorders, panic disorder, obsessive-compulsive disorder, attention deficit hyperactivity disorder, autism spectrum disorder, schizophrenia, treatment of diseases related to neurodegeneration, pain, irritable bowel syndrome.
11. A compound according to claims 1-7 for use as a medicament.
12. Compound according to claim 11, characterized in that it encompasses affective, neurodegenerative, or neurological diseases and disorders in humans caused by abnormalities within the human serotonin system.
13. Compound according to claims 11 or 12, characterized in that said use includes use in the treatment of disorders or conditions resulting from the disturbance of 5-HT? receptordependent signaling transmission such as depression, anxiety disorder, panic disorder, obsessive-compulsive disorder, attention deficit hyperactivity disorder, autism spectrum disorder, schizophrenia, as well as in the treatment of diseases related to neurodegeneration, pain or irritable bowel syndrome.
